Jan, 2002

●

Founded as MEDRx Co., Ltd

Apr, 2005

●

Became Marketing Authorization Holders for Class I & II pharmaceutical products

Aug, 2005

●

Launch a sales of Iodocoat (R) Ointment 0.9%

Aug, 2007

●

Moving of head office

Oct, 2007

●

Established IL Pharma Inc in USA as a subsidiary

Sep, 2009

●

Established a new joint venture company with Kaneka Co.

May, 2010

●

Launch a sales of Amlodipine Oral Jelly used as an anti-hypertensive and in the treatment of angina

Mar, 2011

●

Conclusion of License Agreement for Topical Patch containing etodolac in the U.S. with Kowa Company Ltd.

Mar, 2011

●

Signed License Agreement of the Transdermal Formulation containing NF-κB Decoy Oligonucleotide with AnGes MG Inc.

Feb, 2013

●

Llisted on Tokyo Stock Exchange Mothers Index

Apr, 2015

●

Established MEDRx USA INC in USA as a subsidiary

Oct, 2015

●

Merger IL Pharma Inc. and MEDRx USA INC. ,with MEDRx USA as the surviving company

Apr, 2017

●

Sined a worldwide licensing agreement (except for East Asia) with Cipla USA Inc. to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity